U.S. Poised to Reclassify Marijuana in Historic Shift on Federal Drug Policy
By [Your Name], Senior Correspondent
Washington, D.C. – In a landmark move that could reshape America’s decades-long stance on cannabis, the U.S. Justice Department is expected to reclassify marijuana from its current status as a highly restricted Schedule I drug to a lower-risk category, according to a source familiar with the matter. The long-anticipated decision, which may be finalized as early as Wednesday, marks the most significant federal policy shift on marijuana since the Controlled Substances Act was enacted in 1970.
The proposed reclassification—moving cannabis to Schedule III, alongside substances like ketamine and anabolic steroids—would not legalize it federally but would acknowledge its accepted medical uses and lower potential for abuse compared to drugs like heroin or LSD. The move follows a recommendation from the Department of Health and Human Services (HHS) last year, which cited extensive scientific review and growing public acceptance of marijuana’s therapeutic benefits.
A Turning Point in U.S. Drug Policy
For over half a century, marijuana has been classified as a Schedule I substance under federal law, a category reserved for drugs deemed to have “no currently accepted medical use” and a “high potential for abuse.” This classification has placed cannabis in the same legal category as heroin and ecstasy, despite its legalization for medical or recreational use in 38 states. The dissonance between state and federal law has created a patchwork of legal ambiguities, hindering research, banking access, and interstate commerce for the multibillion-dollar cannabis industry.
The Biden administration’s move aligns with broader public sentiment. A 2023 Gallup poll found that 70% of Americans support marijuana legalization, a record high reflecting a dramatic shift from just 12% approval in 1969. Advocates argue that reclassification is a critical first step toward modernizing federal drug policy, though critics warn it may not go far enough to address disparities in drug enforcement or fully decriminalize cannabis.
Economic and Social Implications
Industry analysts say the reclassification could unleash significant economic opportunities. By easing restrictions, cannabis businesses—which have long operated in a legal gray area—may gain access to tax deductions, banking services, and institutional investment currently blocked by federal prohibition. Under current tax code Section 280E, marijuana companies cannot deduct standard business expenses, leaving many struggling under crippling effective tax rates as high as 70%.
“Rescheduling to Schedule III would be a seismic shift for the industry,” said John Hudak, a senior fellow at the Brookings Institution specializing in cannabis policy. “It won’t solve every problem, but it opens doors for research, medical applications, and financial normalization.”
However, the change falls short of full legalization, meaning state-licensed cannabis businesses would still violate federal law. This could perpetuate conflicts between state and federal jurisdictions, particularly in areas like employment law, where workers in legal states have been fired for off-duty cannabis use.
Medical and Scientific Advancements
Researchers have long criticized the Schedule I classification as a barrier to rigorous scientific study. Despite evidence supporting marijuana’s efficacy in treating chronic pain, epilepsy, and chemotherapy-induced nausea, federal restrictions have stifled large-scale clinical trials. A Schedule III designation could facilitate more research, paving the way for FDA-approved cannabis-based medications.
Dr. Nora Volkow, director of the National Institute on Drug Abuse, has previously acknowledged that cannabis’s current classification is “not tenable” given modern scientific understanding. Studies have shown that while marijuana carries risks—particularly for adolescent brain development—its potential for addiction and overdose is far lower than that of opioids or alcohol.
Political and Legal Road Ahead
The Justice Department’s proposal will undergo a formal rulemaking process, including a public comment period, before taking effect. While the move is likely to face opposition from some lawmakers—particularly conservative critics who argue it could increase youth access—momentum for reform has grown bipartisan support.
Senate Majority Leader Chuck Schumer (D-NY) hailed the expected shift as “a step toward justice,” while Republican Rep. Nancy Mace (R-SC), a proponent of cannabis reform, called it “long overdue.” Still, advocates for broader legalization, including the ACLU, argue that rescheduling alone does little to address the racial inequities of the War on Drugs, which has disproportionately targeted Black and Latino communities.
Global Context
The U.S. decision comes amid a global reassessment of cannabis policies. Countries like Canada, Germany, and Mexico have moved toward legalization or decriminalization, while the United Nations recently reclassified cannabis in a nod to its medical utility. The American shift could embolden other nations to revisit their own drug laws, particularly in regions where U.S. policy has historically influenced international standards.
A Cautious Step Forward
While the Biden administration’s move signals a historic departure from decades of stringent prohibition, experts caution that the practical impact may be incremental. For millions of Americans living in states with legal cannabis, little may change immediately. Yet for policymakers, researchers, and businesses, the reclassification offers a foundation for future reform—one that acknowledges both the evolving science and the undeniable reality of cannabis’s place in American society.
As the nation awaits the Justice Department’s final decision, one thing is clear: the era of treating marijuana as a dangerous narcotic is coming to an end. The question now is whether this shift will be the first step toward broader legalization—or merely a compromise in a still-unfolding debate.
